Skip to main content
. 2020 Apr 27;103(1):132–141. doi: 10.4269/ajtmh.19-0738

Figure 6.

Figure 6.

Kinetics for the median (Q1/Q3) frequency (%) of DENV-type–specific memory B cells (by ELISpot) up to study end (ATP cohort for immunogenicity). ATP = according-to-protocol; DENV = dengue virus; ELISpot = enzyme-linked immunospot assay; N = number of participants in each group; M = month; Q1/Q3 = first and third quantiles; 0–1 M = participants receiving two doses of adjuvant system 03B-adjuvanted inactivated tetravalent dengue virus vaccine (DPIV+AS03B) administered 1 M apart, at M0 and M1; 0–3 M = participants receiving two doses of DPIV+AS03B administered 3 M apart, at M3 and M6; 0–1–6 M = participants receiving three doses of DPIV+AS03B with the first two given 1 M apart and the third given 6 M after the first, at M0, M1, and M6. Error bars depict interquartile ranges.